Sweden · Delayed Price · Currency is SEK CellaVision AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 revenue fell 14.6% year-over-year due to EMEA inventory adjustments, while Americas and APAC delivered strong growth. New product launches and a major software upgrade are expected to drive H2 recovery, with EMEA sales seen improving in Q2.
Fiscal Year 2025
-
Q4 2025 saw robust growth in the Americas and EMEA, offsetting a softer APAC, with full-year organic growth at 9%. Strategic milestones included a CE Mark for the bone marrow application and a major software upgrade, while a dividend increase to SEK 2.75 per share is proposed.
-
Net sales declined 1.7% to SEK 176 million, but organic growth was 2.6% year-over-year, with EBITDA margin rising to 28%. Strategic milestones include a completed clinical trial and software upgrade, while regional performance was mixed and APAC showed lumpy but positive trends.
-
Q2 2025 saw robust results with SEK 191 million revenue and nearly 8% organic growth, led by APAC. Gross margin rose to 68%, and EBITDA margin was 31%. Strategic launches and R&D investments continue, with the bone marrow module set for 2026 commercial launch.
-
Revenue grew 14% year-over-year to SEK 195 million, with strong gross margin at 70% and robust growth across all regions and product lines. Increased R&D investment and strategic partnerships are driving innovation and market share gains, while FX and competitive pressures remain key risks.
Fiscal Year 2024
-
Q4 2024 saw mixed regional results: strong APAC growth, modest EMEA, and a decline in Americas, leading to -7% organic growth. Gross margin was 69% and EBITDA margin 33%. Strategic partnership with Sysmex and ongoing innovation investments position the company for recovery and future growth.
-
Q3 delivered 9% organic revenue growth, led by record EMEA sales and improved gross margin, while Americas faced a 20% decline due to political uncertainty. R&D investment rose to 22% of sales, with key product launches and regulatory milestones on track for 2025.
-
Q2 saw 11% revenue growth and a 32% EBITDA margin, with APAC delivering record results and EMEA showing steady gains. Operational issues in Americas are seen as temporary, while price increases and innovation investments are set to boost margins and growth in H2 2024.